Acriva UD Reviol multifocal intraocular lens in patients undergoing cataract surgery--6-month follow-up.

PURPOSE: To evaluate visual outcomes and complications in patients after binocular Acriva UD Reviol MFB 625 (VSY Biotechnology) multifocal intraocular lens implantation. METHODS: 40 eyes of 20 patients were reassessed at six months following bilateral IOL implantation. The following were evaluated: binocular UDVA and near, binocular uncorrected intermediate visual acuity, spectacle independence, uncorrected binocular photopic contrast sensitivity for distance and near, uncorrected binocular mesopic contrast sensitivity for distance (CS-CSV-1000, F.A.C.T.); stereoscopic vision (Lang Stereotest II), patient satisfaction, subjective symptoms (modified NE VFQ-25) and postoperative complications. RESULTS: Six months after surgery the mean binocular UDVA was logMAR -0.05 ± 0.07, UIVA was +0.04 ± 0.09 and uncorrected near visual acuity was +0.06 ± 0.08. At six months postoperatively, all patients were totally spectacle-independent. Contrast sensitivity under different conditions was within the normal range at all spacial frequencies. Stereoscopic vision was normal in all patients. Low level of glare/halo perception was detected in 55% of patients. General vision quality was high and rated as 1.85 (1--the best, 5--the worst). No severe postoperative complications were observed. CONCLUSION: Cataract surgery with Acriva UD Reviol MFB 625 implantation in a selected group of patients was very effective for all distances and provided excellent patient satisfaction.